NEW YORK, Dec. 14, 2020 /PRNewswire/ -- Immunic,
Inc. (Nasdaq: IMUX), a clinical-stage
biopharmaceutical company developing a pipeline of selective oral
immunology therapies aimed at treating chronic inflammatory and
autoimmune diseases, today announced that it has been selected for
addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective
prior to market open on Monday, December 21,
2020.
The NASDAQ Biotechnology Index is designed to track the
performance of a set of securities listed on The Nasdaq Stock
Market® (NASDAQ®) that are classified as either biotechnology or
pharmaceutical according to the Industry Classification Benchmark.
The NASDAQ Biotechnology Index is re-ranked annually. All
securities in the index are listed on the NASDAQ Global Market or
the NASDAQ Global Select Market and meet minimum market value and
share volume requirements, among other criteria.
The NASDAQ Biotechnology Index forms the basis for a number of
Exchange Traded Funds (ETFs), including the iShares NASDAQ
Biotechnology ETF (Nasdaq: IBB). More information about the Index
can be found at
https://indexes.nasdaqomx.com/Index/Overview/NBI.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a
clinical-stage biopharmaceutical company with a pipeline of
selective oral immunology therapies aimed at treating chronic
inflammatory and autoimmune diseases, including relapsing-remitting
multiple sclerosis, ulcerative colitis, Crohn's disease, and
psoriasis. Immunic is developing three small molecule products: its
lead development program, IMU-838, is a selective immune modulator
that inhibits the intracellular metabolism of activated immune
cells by blocking the enzyme DHODH and exhibits a host-based
antiviral effect; IMU-935 is an inverse agonist of RORγt; and
IMU-856 targets the restoration of the intestinal barrier function.
Immunic announced positive results from its phase 2 EMPhASIS trial
of IMU-838 in patients with relapsing-remitting multiple sclerosis,
reporting achievement of both primary and key secondary endpoints
with high statistical significance. IMU-838 is also in phase 2
clinical development for ulcerative colitis and COVID-19, with an
additional phase 2 trial considered in Crohn's disease. An
investigator-sponsored proof-of-concept clinical trial for IMU-838
in primary sclerosing cholangitis is ongoing at the Mayo Clinic.
For further information, please visit: www.imux.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements" that involve substantial risks and uncertainties for
purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995. All statements, other than
statements of historical facts, included in this press release
regarding strategy, future operations, future financial position,
future revenue, projected expenses, prospects, plans and objectives
of management are forward-looking statements. Examples of such
statements include, but are not limited to, statements relating to
Immunic's stock being added to the NASDAQ Biotechnology Index,
Immunic's three development programs and the targeted diseases; the
potential for IMU-838, IMU-935 and IMU-856 to safely and
effectively target diseases; the nature, strategy and focus of the
company; and the development and commercial potential of any
product candidates of the company. Immunic may not actually achieve
the plans, carry out the intentions or meet the expectations or
projections disclosed in the forward-looking statements and you
should not place undue reliance on these forward-looking
statements. Such statements are based on management's current
expectations and involve risks and uncertainties. Actual results
and performance could differ materially from those projected in the
forward-looking statements as a result of many factors, including,
without limitation, the COVID-19 pandemic, risks and uncertainties
associated with the ability to project future cash utilization and
reserves needed for contingent future liabilities and business
operations, the availability of sufficient resources to meet
business objectives and operational requirements, the fact that the
results of earlier studies and trials may not be predictive of
future clinical trial results, the protection and market
exclusivity provided by Immunic's intellectual property, risks
related to the drug development and the regulatory approval process
and the impact of competitive products and technological changes. A
further list and descriptions of these risks, uncertainties and
other factors can be found in the section captioned "Risk Factors,"
in the company's Annual Report on Form 10-K for the fiscal year
ended December 31, 2019, filed with
the SEC on March 16, 2020, the
company's Quarterly Report on Form 10-Q for the quarter ended
September 30, 2020, filed with the
SEC on November 6, 2020, and in the
company's subsequent filings with the Securities and Exchange
Commission. Copies of these filings are available online at
www.sec.gov or ir.imux.com/sec-filings. Any forward-looking
statement made in this release speaks only as of the date of this
release. Immunic disclaims any intent or obligation to update these
forward-looking statements to reflect events or circumstances that
exist after the date on which they were made. Immunic expressly
disclaims all liability in respect to actions taken or not taken
based on any or all the contents of this press release.
Contact Information
Immunic, Inc.
Jessica
Breu
Head of Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
Rx Communications Group
Melody Carey
+1 917 322 2571
immunic@rxir.com
US Media Contact
KOGS Communication
Edna Kaplan
+1 781 639 1910
kaplan@kogspr.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/immunic-inc-added-to-nasdaq-biotechnology-index-301191897.html
SOURCE Immunic, Inc.